Skip to content

The Possible Role of Thyroxine in Keratoconus Development

The Possible Role of Thyroxine in Keratoconus Development

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03637673
Enrollment
150
Registered
2018-08-20
Start date
2018-06-01
Completion date
2018-09-15
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratoconus

Brief summary

Keratoconus (KC) is a corneal ectatic disorders, with incidence rate 1 per 50,000 among the population. Hormonal imbalances may be associated with KC as it affects the corneal metabolism. In this study, we aim to examine this clinical association between thyroid gland dysfunction (TGD) and KC.

Detailed description

Keratoconus (KC) is a corneal ectatic disorders, with incidence rate 1 per 50,000 among the population. Moreover, the pathophysiological processes underlying KC have not been fully elucidated with proposed mechanisms to include proteolytic degradation in the corneal stroma, oxidative damage, epithelial mechanical injury, immunological factors, and genetic factors. However, Hormonal imbalances may be associated with KC as it affects the corneal metabolism. Furthermore, thyroid gland dysfunction (TGD) can frequently associated with eye diseases such as Graves disease. Previous studies investigated the association between TGD and KC. Interestingly, thyroxine (T4) is important for corneal dehydration and transparency during embryonic development and regulates the synthesis of keratin sulfate proteoglycan in the chicken. T4 receptors (T4Rs) have been found in the lacrimal gland, confirming that the tear producing gland is a target organ of T4. T4 level was elevated in the tears of patients with KC. Hence, in this study, we aim to investigate the clinical association between TGD and KC.

Interventions

OTHERNo intervention

No intervention

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients with KC.

Exclusion criteria

* Patients who cannot give an informed consent. * Patients who cannot provide needed samples for any reason

Design outcomes

Primary

MeasureTime frameDescription
measuring the serum concentrations of free T4 (fT4) and thyroid-stimulating hormone (TSH)We will recruit patients who meet the inclusion criteria during the study period of 3 months (June- August 2018). We will take only one blood sample from each patient recruited after the recrutiement and during this periodThe endocrinologic examination will include measuring the serum concentrations of free T4 (fT4) and thyroid-stimulating hormone (TSH) using an immunoassay method (ADVIA Centaur; Bayer Diagnostics, Germany). The normal reference ranges for TSH and fT4 were determined to be 0.35 to 4.5 mIU/ L and 0.7 to 1.65 ng/dL, respectively. Clinical cases with fT4 serum concentrations beyond these reference ranges will be defined as TGD. All examinations will be handled anonymously.

Countries

Egypt

Contacts

Primary ContactAmir Abousamra, Ph.D.
amirabousamra69@gmail.com00201005084303
Backup ContactMohamed Fahmy Doheim
fahmydehim21@gmail.com001221081590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026